Search
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients … given an antibacterial treatment for recurrent CDI.
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]
Triflupromazine
go.drugbank.com/drugs/DB00508ApprovedVet approvedA phenothiazine used as an antipsychotic agent and as an antiemetic.
Thyroid, porcine
go.drugbank.com/drugs/DB09100ApprovedInvestigational[A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSuch capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. … The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established.
Romiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalRomiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Indocyanine green acid form
go.drugbank.com/drugs/DB09374ApprovedInvestigationalThe chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide,
Categories: Compounds used in a research, industrial, or household settingCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region.
Products: CIMZIA 200MG PEN, CIMZIA 200 MG ILO IN FER